Search Results for: -j3ur55.html

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced enrollment of the first patients with first-line advanced pancreatic cancer in a phase 2 study of 9-ING-41, as a new arm of the ongoing phase 1/2 1801 trial of 9-ING-41, (NCT03678883, EudraCT#:2018-003739-32). 9-ING-41 is Actuate’s proprietary small […]

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today that interim results from their 1801 Phase 1/2 study (NCT03678883, EudraCT #: 2018-003739-32) will be presented at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting which will take place virtually on May 29th, 2020. Dr.

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced the initiation of two additional clinical studies with its lead molecule, 9-ING-41, a Glycogen Synthase Kinase beta (GSK-3β) inhibitor. On April 8, the company opened its 1902 study: A Phase 1 study of 9-ING-41, a Glycogen Synthase

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced it has raised an additional $6.5M in a Series B-3 financing round. This Series B-3 was led by Bios Partners with Kairos Ventures, DEFTA Partners, and other existing investors participating, and brings total funding for Actuate’s Series B